PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pharmaceutical Care, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia. Electronic address: Hajar.alqahtani99@gmail.com.\', \'Department of Pharmaceutical Care, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.\', \'Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.\', \'College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.\', \'Department of Infection Prevention and Control, Ministry of National Guard, Health Affairs, Riyadh, Saudi Arabia.\', \'Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.\', \'College of Pharmacy, Department of Pharmaceutics, King Saud University, Riyadh, Saudi Arabia.\', \'Department of Intensive Care, King Abdulaziz Medical City, Riyadh, Saudi Arabia.\', \'Department of Medicine, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; Department of Clinical Trial Services, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1876-0341(21)00380-410.1016/j.jiph.2021.11.017
?:hasPublicationType
?:journal
  • Journal of infection and public health
is ?:pmid of
?:pmid
?:pmid
  • 34883296
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.648
?:rankingScore_hIndex
  • 23
is ?:relation_isRelatedTo_publication of
?:title
  • Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all